Advertisement

Topics

Rafael Pharmaceuticals to Present New Data Validating Efficacy and Tolerability of CPI-613 in Treating Acute Myeloid Leukemia at the 23rd Congress of the European Hematology Association

20:00 EDT 13 Jun 2018 | Globe Newswire

Newark, NJ, June 14, 2018 (GLOBE NEWSWIRE) -- CPI-613 is Rafael Pharmaceuticals' lead drug candidate, a first-in-class anticancer compound designed to disrupt the altered energy production pathways in cancer cells by targeting mitochondrial metabolism.

EHA Presentation Details

  1. Pharmacologic inhibition of cellular metabolic processes impacted by aging sensitize acute myeloid leukemia (AML) cells to the novel lipoate derivative CPI-613
    • Date/Time: Saturday, June 16, 2018 from 17:30 - 19:30
    • Type: Poster Presentation 
    • Location: Stockholmsmässan: Mässvägen 1, 125 80 Älvsjö, Sweden - Poster Area
    • Abstract #: PS939
    • Link to abstract 
    • Scheduled Presenters: Timothy S. Pardee, M.D., Ph.D., CMO of Rafael Pharmaceuticals, and Sanjeev Luther, President & CEO of Rafael Pharmaceuticals
  1. Analysis of Phase I and pilot Phase II data reveal 2,000 MG/M2 as the optimal dose of CPI-613 in combination with cytarabine and mitoxantrone for elderly patients with relapsed or refractory AML
    • Date/Time: Saturday, June 16, 2018 from 17:30 - 19:30
    • Type: Poster Presentation 
    • Location: Stockholmsmässan: Mässvägen 1, 125 80 Älvsjö, Sweden - Poster Area
    • Abstract #: PS998 
    • Link to abstract
    • Scheduled Presenters: Timothy S. Pardee, M.D., Ph.D., CMO of Rafael Pharmaceuticals, and Sanjeev Luther, President & CEO of Rafael Pharmaceuticals

    
INTERVIEW: Dr. Pardee and Sanjeev Luther, Rafael Pharmaceuticals’ CMO, and President and CEO respectively, will be available for media interviews upon request.

CONTACT: Jacob Jonas, jacob.jonas@rafaelpharma.com, for more information.

About Rafael Pharmaceuticals, Inc.

Rafael Pharmaceuticals, Inc. is a clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael’s primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Rafael’s first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. CPI-613 has been granted orphan drug designation for the treatment of pancreatic cancer, AML, myelodysplastic syndromes (MDS), Burkitt’s lymphoma, and T-cell lymphoma. For more information, visit http://www.rafaelpharma.com/.

Primary Logo

NEXT ARTICLE

More From BioPortfolio on "Rafael Pharmaceuticals to Present New Data Validating Efficacy and Tolerability of CPI-613 in Treating Acute Myeloid Leukemia at the 23rd Congress of the European Hematology Association"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...